|
||||
Medicare Part A
|
![]() |
Provider Notice: 05-209 Medlearn Matters Number: MM4206 Original Issue Date: December 30, 2005 FROM: Medicare Communications SUBJECT: Healthcare Common Procedure Coding System (HCPCS) Updates to the Fiscal Intermediary Shared System (FISS) Edit for Epoetin Alfa and Darbepoetin Alfa This bulletin should be shared with all health care practitioners and managerial members of the provider/supplier staff. Additional copies may be downloaded from our website at www.highmarkmedicareservices.com Coming in 2006! Beginning January 1, 2006, Medicare prescription drug coverage will be available to people with Medicare. Health care professionals can find information about this new coverage at www.cms.hhs.gov/medlearn/drugcoverage.asp, on the CMS website. Announcing the new CMS web page dedicated to providing all the latest NPI news for Fee-For-Service (FFS) Medicare providers! Visit http://www.cms.hhs.gov/NationalProvIdentStand/ on the web! While this page is dedicated to the Medicare FFS community, it contains helpful information and links that may benefit all health care providers. Reminder--Health care providers are required by law to apply for a National Provider Identifier (NPI).To apply online, visit: https://nppes.cms.hhs.gov Related Change Request (CR) #: 4206 Providers Type Affected:Providers billing Medicare fiscal intermediaries (FIs) for services related to the administration of Epoetin Alfa and Darbepoetin Alfa to Medicare beneficiaries Providers Action Needed:STOP - Impact to You
This article is based on Change Request (CR) 4206, which terminates the Q codes for Epoetin Alfa and Darbepoetin Alfa and replaces them with J codes. CAUTION - What You Need to KnowEffective January 1, 2006: Q0136 Epoetin Alfa for Non-ESRD use is replaced with J0885; Q0137 Darbepoetin Alfa for Non-ESRD use is replaced with J0881; Q4054 Darbepoetin Alfa for ESRD use is replaced with J0882; and Q4055 Epoetin Alfa for ESRD use is replaced with J0886. GO - What You Need to DoSee the Background section of this article for further details regarding these changes. Background:The annual Healthcare Common Procedure Coding System (HCPCS) update effective January 1, 2006, changes the HCPCS for reporting and billing Epoetin Alfa and Darbepoetin Alfa. CR4206 terminates Q codes for Epoetin Alfa and Darbepoetin Alfa and replaces them with the J codes shown below, effective January 1, 2006:
Note: CR4108 (Transmittal 737, dated October 31, 2005, http://www.cms.hhs.gov/transmittals/downloads/R737CP.pdf ) instructs providers to begin billing the new HCPCS effective January 1, 2006. The corresponding Medlearn Matters article (MM 4108) can be found at http://cms.hhs.gov/MLNMattersArticles/downloads/MM4108.pdf All billing and payment instructions currently required for the Q codes in the Medicare Claims Processing Manual (Publication 100-4, Chapter 8, Section 60 (Separately Billable ESRD Items and Services), found at http://cms.hhs.gov/manuals/downloads/clm104c08.pdf on the CMS web site, will be applied to the new J codes upon implementation of this instruction. According to CR4206, there are no other changes to the reporting and payment of Epoetin Alfa and Darbepoetin Alfa. Implementation:The implementation date for the instruction is April 3, 2006. Claims submitted on types of bills 12x, 13x, and 85x that contain J0882 and/or J0886 between the effective date and the April 3, 2006, implementation date will be paid on a reasonable cost basis. However, the Medicare intermediaries will automatically adjust these claims after the implementation date and correct the payment and pay affected claims based on the appropriate fee. Additional Information:For complete details, please see the official instruction issued to your intermediary regarding this change. That instruction may be viewed at http://www.cms.hhs.gov/transmittals/downloads/R772CP.pdf on the CMS web site. Assistance:If you have any questions regarding this bulletin, please contact the appropriate Customer Contact Center at: Maryland Providers: 1-866-488-0545 |
||
|
© 2005-2008. All rights are reserved.
|
||||